NCT01487382已完成不适用
Special Survey for Paediatric Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 241
- 主要终点
- Hypoglycaemic events
研究概览
简要总结
This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using NovoRapid® (insulin aspart) in children with type 1 and type 2 diabetes under normal clinical practice conditions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 15 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Requiring insulin therapy
- •No treatment history of NovoRapid® (insulin aspart)
排除标准
- 未提供
研究组 & 干预措施
Insulin Aspart
干预措施: insulin aspart (Drug)
结局指标
主要结局
Hypoglycaemic events
次要结局
- HbA1c (glycosylated haemoglobin)
- Physicial examination
- Adverse events
研究者
相似试验
已完成
不适用
Paediatric Subjects - Special SurveyDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT01538576Novo Nordisk A/S71
已完成
3 期
A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 YearsHealthy Japanese Children Age 7 Years Through 18 YearsNCT02269475AstraZeneca1,369
已完成
3 期
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid ArthritisJuvenile Rheumatoid ArthritisNCT00095173Bristol-Myers Squibb214
已完成
不适用
Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner SyndromeGrowth Hormone Deficiency in ChildrenGrowth Hormone DisorderGenetic DisorderTurner SyndromeNCT01604161Novo Nordisk A/S2,016
已完成
不适用
Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus LetrozoleBreast CancerNCT04735367Pfizer42